About EPNextS
Management Philosophy
- Our Mission
- We will contribute to the advancement of the healthcare industry by providing high-value-added solutions to our clients.
- Our Vision
- If we improve each day, we can progress ourselves daily and will continue to do so.
Ever Progressing System
- Our Values
-
For our Clients
We always place the highest priority on meeting clients’ needs and providing high-value-added services.
For our Business
We will contribute to the advancement of society through sustained development of our businesses.
For our People
We will grow through our service to clients, and improve the quality of life (QOL) of all our stakeholders.
Company Profile
- Corporate Name
- EPNextS, Inc.
- Representative Director
- Tatsuma NAGAOKA
- Registered address
- TSUKUDO TERRACE, 2-1 TsukudoHachimancho, Shinjuku-ku,
Tokyo 162-0815, Japan
- Establishment
- October 4, 2022
- Capital
- 100 million yen
- Business Overview
- Overseeing clinical trial business and post-marketing business to create new business solutions in the healthcare sector
Leadership Team
Board Members and
Statutory Auditors
As of May 1, 2025
- Representative Director
- Tatsuma NAGAOKA
- Board Member
- Akira SASA
- Board Member
- Takehisa YAMADA
- Board Member
- Kenichi YAMAMOTO
- Director (Part-time)
- Kazuki SEKITANI
- Director (Part-time)
- Sadahiro SUGITA
- Board Member (External)
- Toshio SHIMADA
- Board Member (External)
- Junichi TAGUCHI
- Board Member (External)
- Aya YOKOYAMA
- Audit & Supervisory Board Member
- Shinji KAMIYA
Executive Officer
As of October 1, 2025
- President and Representative Executive Officer
- Tatsuma NAGAOKA
- Senior Managing Executive Officer
- Akira SASA
- Senior Managing Executive Officer
- Takehisa YAMADA
- Managing Executive Officer
- Kenichi YAMAMOTO
- Senior Executive Officer
- Hisayuki YOKOSE
- Senior Executive Officer
- Kanami IKEDA
- Senior Executive Officer
- Takuya KUSABA
- Senior Executive Officer
- Mitsuyoshi NAGATSUMA
- Senior Executive Officer
- Kenji SAKUMA
Address
TSUKUDO TERRACE, 2-1 Tsukudohachimancho,
Shinjuku-ku, Tokyo, Japan
TEL：+81-3-4586-5435
JR Iidabashi Stn. East Exit
Subway Iidabashi Stn.Exit B1,C1
Our History
-
1991
E.P.S. Tokyo, Co., Ltd. was started with three employees, focusing on the development of “systems to manage treatment allocation and trial progress” and “GCP management systems” to manage clinical trials scientifically and ethically.
The company received investment from Fudan University in China and changed its name to EPS Tokyo Inc. -
1993
We were contracted to develop a support system for two large-scale clinical trials (the “MEGA Study” and the “ATHEROMA Study”) as part of the Ministry of Health and Welfare’s drug epidemiology research. In addition, data center operations have begun for both studies.
-
1996
Company name changed to EPS Co., Ltd.
-
1999
We started operations in Shanghai as the first full-fledged contract research organization (CRO) in China.
We started our SMO business to support clinical trial-related operations of medical institutions. Since then, through several mergers, the EPS Group’s SMO business has grown to hold the No. 1 market share in the industry. -
2000
Started CSO (Contract Sales Organization) business, which undertakes MR (Medical Representative) operations for pharmaceutical companies.
-
2001
We became the first CRO to go public.
EPS Corporation listed on JASDAQ. -
2003
Launched CRO business in Southeast Asia.
-
2006
EPS Corporation listed on the 1st section of the Tokyo Stock Exchange.
-
2010
Started Pharmaceutical products sales business in China.
-
2015
Transferred to a holding company system and changed the company name to EPS Holdings, Inc.
-
2016
Capital and business alliance agreement with SUZUKEN CO., LTD.
-
2020
Participation in joint development of DNA vaccine for new coronavirus (COVID-19).
-
2021
30th anniversary of the foundation.
MBO implemented and unlisted. -
2022
TSUKUDO TERRACE, our own building was completed.
-
2023
EPNextS, Inc. started full operation overseeing our core businesses of EPS group (CRO, SMO, CSO) .